“Unraveling the Threads of Cancer’s Complexity”

Mission Bio is a single-cell multi-omics platform. They give doctors the ability to zero in on a single cell to observe both genotype and phenotype impacts from the use of various therapies during clinical trials. Mission Bio’s product, Tapestri, can detect both protein and DNA changes within a single cell. This is groundbreaking when determining the effectiveness of targeted cell therapies because doctors can isolate the impact of other outside variables.

Charlie Silver invited Mighty Capital to invest alongside Mayfield and Agilent in an oversubscribed round because of our invaluable network. It paid off because one of our introductions led to him hiring the former CEO of Sony BioScience.